<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096667</url>
  </required_header>
  <id_info>
    <org_study_id>8835-042</org_study_id>
    <secondary_id>B1521004</secondary_id>
    <secondary_id>MK-8835-042</secondary_id>
    <nct_id>NCT01096667</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)</brief_title>
  <official_title>A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational
      drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and
      hypertension. Participants in the study will receive 1 of 5 treatments for 28 days (either
      placebo, 1 of 3 doses of ertugliflozin [1, 5, or 25 mg], or the approved drug
      hydrochlorothiazide [HCTZ]). The primary hypothesis of the study was that ertugliflozin was
      superior to placebo on the change from baseline in average, 24-hour systolic blood pressure
      (SBP) on Day 28.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2010</start_date>
  <completion_date type="Actual">February 25, 2011</completion_date>
  <primary_completion_date type="Actual">February 9, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline 24-hour Average Systolic Blood Pressure (SBP)</measure>
    <time_frame>24 hours</time_frame>
    <description>Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline on 24-hour Average SBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline Average Daytime and Nighttime SBP</measure>
    <time_frame>Daytime: 16 hours; Nighttime: 8 hours</time_frame>
    <description>Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Daytime Average SBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Nighttime Average SBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Seated, Triplicate Trough SBP</measure>
    <time_frame>Baseline</time_frame>
    <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated, Triplicate Trough SBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on 24-hour Average DBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Daytime Average DBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Nighttime Average DBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Seated, Triplicate Trough DBP</measure>
    <time_frame>Baseline</time_frame>
    <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated, Triplicate Trough DBP at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline 24-hour, Daytime and Nightime Average Heart Rate</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on 24-hour Average Heart Rate at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Daytime Average Heart Rate at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on Nighttime Average Heart Rate at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Seated, Triplicate Trough Heart Rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline 24-hour Average Urinary Glucose Excretion</measure>
    <time_frame>24 hours</time_frame>
    <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours). In the case of missing data, LOCF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline</time_frame>
    <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Adverse Event (AE)</measure>
    <time_frame>Up to 63 days (including run-in, treatment period, and follow-up)</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to 28 days (treatment period)</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertuglilflozin 1 or 5 mg</intervention_name>
    <description>Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 1 mg</intervention_name>
    <description>Ertugliflozin tablet 1 mg once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin tablet 5 mg once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 25 mg</intervention_name>
    <description>Ertugliflozin tablet 25 mg once daily for 28 days</description>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ 12.5mg</intervention_name>
    <description>Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days</description>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to HCTZ</intervention_name>
    <description>Placebo to HCTZ 12.5 mg capsule once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ertuglilflozin 25 mg</intervention_name>
    <description>Placebo to ertuglilflozin tablet 25 mg once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>HCTZ 12.5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with type 2 diabetes and hypertension

          -  Medically stable

          -  On at least 1 (and up to 2) oral diabetes drugs

          -  And up to 2 medicines for blood pressure control

        Exclusion Criteria:

          -  Participants with type 1 diabetes

          -  Heart attack

          -  Stroke

          -  Uncontrolled blood pressure

          -  Significant kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
    <country>Malaysia</country>
    <country>Puerto Rico</country>
    <country>Serbia</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015 Aug;17(8):805-8. doi: 10.1111/dom.12486. Epub 2015 Jun 17.</citation>
    <PMID>25951755</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <results_first_submitted>November 15, 2017</results_first_submitted>
  <results_first_submitted_qc>November 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <disposition_first_submitted>April 10, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 10, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2013</disposition_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>hypertension</keyword>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, 194 participants received placebo for at least 3 weeks (completed the run-in period). Treated participants included all randomized participants who received at least one dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to hydrochlorothiazide (HCTZ), once daily for 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="P4">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="P5">
          <title>HCTZ 12.5mg</title>
          <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population includes participants who received at least 1 dose of blinded treatment regimen.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="B5">
          <title>HCTZ 12.5mg</title>
          <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="39"/>
            <count group_id="B6" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline 24-hour Average Systolic Blood Pressure (SBP)</title>
        <description>Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).</description>
        <time_frame>24 hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline 24-hour Average Systolic Blood Pressure (SBP)</title>
          <description>Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM).</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.11" spread="15.298"/>
                    <measurement group_id="O2" value="133.13" spread="10.868"/>
                    <measurement group_id="O3" value="135.08" spread="12.073"/>
                    <measurement group_id="O4" value="135.59" spread="11.929"/>
                    <measurement group_id="O5" value="139.55" spread="11.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline on 24-hour Average SBP at Week 4</title>
        <description>Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on 24-hour Average SBP at Week 4</title>
          <description>Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF).</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" lower_limit="-1.31" upper_limit="1.70"/>
                    <measurement group_id="O2" value="-2.71" lower_limit="-4.15" upper_limit="-1.33"/>
                    <measurement group_id="O3" value="-3.73" lower_limit="-5.30" upper_limit="-2.18"/>
                    <measurement group_id="O4" value="-3.42" lower_limit="-4.86" upper_limit="-1.99"/>
                    <measurement group_id="O5" value="-2.95" lower_limit="-4.39" upper_limit="-1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.97</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.00</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>-1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.69</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.78</ci_lower_limit>
            <ci_upper_limit>-1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.21</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.30</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Average Daytime and Nighttime SBP</title>
        <description>Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>Daytime: 16 hours; Nighttime: 8 hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for daytime and nighttime SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Average Daytime and Nighttime SBP</title>
          <description>Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for daytime and nighttime SBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.95" spread="15.107"/>
                    <measurement group_id="O2" value="136.85" spread="11.361"/>
                    <measurement group_id="O3" value="138.89" spread="11.724"/>
                    <measurement group_id="O4" value="139.56" spread="12.343"/>
                    <measurement group_id="O5" value="143.32" spread="12.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.54" spread="16.858"/>
                    <measurement group_id="O2" value="125.15" spread="12.180"/>
                    <measurement group_id="O3" value="126.37" spread="13.956"/>
                    <measurement group_id="O4" value="127.13" spread="13.553"/>
                    <measurement group_id="O5" value="131.68" spread="12.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Daytime Average SBP at Week 4</title>
        <description>Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Daytime Average SBP at Week 4</title>
          <description>Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="-0.90" upper_limit="2.34"/>
                    <measurement group_id="O2" value="-2.88" lower_limit="-4.49" upper_limit="-1.44"/>
                    <measurement group_id="O3" value="-3.61" lower_limit="-5.30" upper_limit="-1.94"/>
                    <measurement group_id="O4" value="-4.17" lower_limit="-5.72" upper_limit="-2.63"/>
                    <measurement group_id="O5" value="-3.10" lower_limit="-4.66" upper_limit="-1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.70</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.94</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.43</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.78</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.99</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.24</ci_lower_limit>
            <ci_upper_limit>-2.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.92</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.16</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Nighttime Average SBP at Week 4</title>
        <description>Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Nighttime Average SBP at Week 4</title>
          <description>Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" lower_limit="-2.28" upper_limit="1.71"/>
                    <measurement group_id="O2" value="-2.48" lower_limit="-4.33" upper_limit="-0.60"/>
                    <measurement group_id="O3" value="-3.47" lower_limit="-5.53" upper_limit="-1.39"/>
                    <measurement group_id="O4" value="-2.31" lower_limit="-4.21" upper_limit="-0.40"/>
                    <measurement group_id="O5" value="-2.30" lower_limit="-4.20" upper_limit="-0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.19</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.93</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.06</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.02</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.01</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.77</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Seated, Triplicate Trough SBP</title>
        <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Seated, Triplicate Trough SBP</title>
          <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough SBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.17" spread="14.183"/>
                    <measurement group_id="O2" value="134.23" spread="13.631"/>
                    <measurement group_id="O3" value="137.31" spread="14.834"/>
                    <measurement group_id="O4" value="135.25" spread="13.452"/>
                    <measurement group_id="O5" value="138.07" spread="12.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated, Triplicate Trough SBP at Week 4</title>
        <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated, Triplicate Trough SBP at Week 4</title>
          <description>Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="-0.93" upper_limit="3.41"/>
                    <measurement group_id="O2" value="-2.77" lower_limit="-4.95" upper_limit="-0.60"/>
                    <measurement group_id="O3" value="-5.92" lower_limit="-8.12" upper_limit="-3.73"/>
                    <measurement group_id="O4" value="-4.96" lower_limit="-7.15" upper_limit="-2.77"/>
                    <measurement group_id="O5" value="-3.13" lower_limit="-5.26" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.01</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.09</ci_lower_limit>
            <ci_upper_limit>-0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-7.16</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.25</ci_lower_limit>
            <ci_upper_limit>-4.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-6.20</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.28</ci_lower_limit>
            <ci_upper_limit>-3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.41</ci_lower_limit>
            <ci_upper_limit>-1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)</title>
        <description>Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>up to 24 hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour, daytime and nighttime DBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline 24-hour, Daytime and Nightime Average Diastolic Blood Pressure (DBP)</title>
          <description>Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour, daytime and nighttime DBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.89" spread="9.655"/>
                    <measurement group_id="O2" value="78.67" spread="8.600"/>
                    <measurement group_id="O3" value="80.18" spread="8.655"/>
                    <measurement group_id="O4" value="80.36" spread="8.650"/>
                    <measurement group_id="O5" value="82.66" spread="9.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.32" spread="10.127"/>
                    <measurement group_id="O2" value="81.77" spread="8.925"/>
                    <measurement group_id="O3" value="83.47" spread="9.164"/>
                    <measurement group_id="O4" value="83.59" spread="9.295"/>
                    <measurement group_id="O5" value="85.87" spread="9.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.24" spread="9.717"/>
                    <measurement group_id="O2" value="72.05" spread="9.330"/>
                    <measurement group_id="O3" value="73.05" spread="9.034"/>
                    <measurement group_id="O4" value="73.28" spread="8.760"/>
                    <measurement group_id="O5" value="75.76" spread="10.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on 24-hour Average DBP at Week 4</title>
        <description>Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on 24-hour Average DBP at Week 4</title>
          <description>Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="-0.25" upper_limit="1.75"/>
                    <measurement group_id="O2" value="-1.89" lower_limit="-2.81" upper_limit="-0.95"/>
                    <measurement group_id="O3" value="-2.34" lower_limit="-3.37" upper_limit="-1.31"/>
                    <measurement group_id="O4" value="-1.50" lower_limit="-2.45" upper_limit="-0.55"/>
                    <measurement group_id="O5" value="-1.42" lower_limit="-2.37" upper_limit="-0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.66</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.03</ci_lower_limit>
            <ci_upper_limit>-1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.11</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.55</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.27</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.65</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.19</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Daytime Average DBP at Week 4</title>
        <description>Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Daytime Average DBP at Week 4</title>
          <description>Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="-0.24" upper_limit="1.85"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-3.13" upper_limit="-1.18"/>
                    <measurement group_id="O3" value="-1.88" lower_limit="-2.96" upper_limit="-0.80"/>
                    <measurement group_id="O4" value="-1.77" lower_limit="-2.77" upper_limit="-0.78"/>
                    <measurement group_id="O5" value="-1.69" lower_limit="-2.67" upper_limit="-0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.99</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.43</ci_lower_limit>
            <ci_upper_limit>-1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.75</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.26</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>-1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate. p-value is one-sided.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.57</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Nighttime Average DBP at Week 4</title>
        <description>Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Nighttime Average DBP at Week 4</title>
          <description>Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="-0.39" upper_limit="2.44"/>
                    <measurement group_id="O2" value="-1.48" lower_limit="-2.78" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-2.52" lower_limit="-3.98" upper_limit="-1.06"/>
                    <measurement group_id="O4" value="-0.84" lower_limit="-2.19" upper_limit="0.51"/>
                    <measurement group_id="O5" value="-0.55" lower_limit="-1.95" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.50</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.43</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.58</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.88</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.148</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Seated, Triplicate Trough DBP</title>
        <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough DBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Seated, Triplicate Trough DBP</title>
          <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough DBP.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.89" spread="9.462"/>
                    <measurement group_id="O2" value="83.08" spread="7.557"/>
                    <measurement group_id="O3" value="83.79" spread="7.904"/>
                    <measurement group_id="O4" value="83.89" spread="8.290"/>
                    <measurement group_id="O5" value="84.72" spread="8.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated, Triplicate Trough DBP at Week 4</title>
        <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough DBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated, Triplicate Trough DBP at Week 4</title>
          <description>Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough DBP.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="-0.97" upper_limit="1.58"/>
                    <measurement group_id="O2" value="-0.90" lower_limit="-2.18" upper_limit="0.37"/>
                    <measurement group_id="O3" value="-0.75" lower_limit="-2.03" upper_limit="0.54"/>
                    <measurement group_id="O4" value="-2.71" lower_limit="-4.00" upper_limit="-1.43"/>
                    <measurement group_id="O5" value="-2.54" lower_limit="-3.79" upper_limit="-1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Measures Repeated Model</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Measures Repeated Model</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.05</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.86</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Measures Repeated Model</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.02</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.83</ci_lower_limit>
            <ci_upper_limit>-1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Measures Repeated Model</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.84</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.63</ci_lower_limit>
            <ci_upper_limit>-1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline 24-hour, Daytime and Nightime Average Heart Rate</title>
        <description>Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>up to 24 hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour, daytime and nighttime heart rate.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline 24-hour, Daytime and Nightime Average Heart Rate</title>
          <description>Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average 24-hour, daytime and nighttime heart rate.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.11" spread="9.486"/>
                    <measurement group_id="O2" value="80.74" spread="6.950"/>
                    <measurement group_id="O3" value="79.68" spread="10.081"/>
                    <measurement group_id="O4" value="79.41" spread="9.063"/>
                    <measurement group_id="O5" value="79.08" spread="9.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.43" spread="9.743"/>
                    <measurement group_id="O2" value="83.74" spread="7.044"/>
                    <measurement group_id="O3" value="82.71" spread="10.405"/>
                    <measurement group_id="O4" value="82.18" spread="9.136"/>
                    <measurement group_id="O5" value="81.95" spread="9.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.05" spread="9.871"/>
                    <measurement group_id="O2" value="74.44" spread="8.133"/>
                    <measurement group_id="O3" value="73.16" spread="10.205"/>
                    <measurement group_id="O4" value="73.49" spread="10.034"/>
                    <measurement group_id="O5" value="73.03" spread="9.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on 24-hour Average Heart Rate at Week 4</title>
        <description>Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on 24-hour Average Heart Rate at Week 4</title>
          <description>Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-0.21" upper_limit="2.16"/>
                    <measurement group_id="O2" value="-1.22" lower_limit="-2.45" upper_limit="-0.25"/>
                    <measurement group_id="O3" value="1.07" lower_limit="-0.16" upper_limit="2.29"/>
                    <measurement group_id="O4" value="-1.39" lower_limit="-2.52" upper_limit="-0.26"/>
                    <measurement group_id="O5" value="-0.56" lower_limit="-1.68" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.22</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.83</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.521</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.07</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.63</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.39</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.02</ci_lower_limit>
            <ci_upper_limit>-0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.56</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.19</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Daytime Average Heart Rate at Week 4</title>
        <description>Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Daytime Average Heart Rate at Week 4</title>
          <description>Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="0.25" upper_limit="2.83"/>
                    <measurement group_id="O2" value="-1.80" lower_limit="-3.09" upper_limit="-0.70"/>
                    <measurement group_id="O3" value="1.10" lower_limit="-0.24" upper_limit="2.43"/>
                    <measurement group_id="O4" value="-1.07" lower_limit="-2.31" upper_limit="0.15"/>
                    <measurement group_id="O5" value="-0.06" lower_limit="-1.22" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.38</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>-1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.65</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.43</ci_lower_limit>
            <ci_upper_limit>-0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.64</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.42</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on Nighttime Average Heart Rate at Week 4</title>
        <description>Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on Nighttime Average Heart Rate at Week 4</title>
          <description>Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and a post-randomization measurement for average, 24-hour SBP.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-1.63" upper_limit="1.25"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-1.76" upper_limit="0.91"/>
                    <measurement group_id="O3" value="1.43" lower_limit="-0.07" upper_limit="2.92"/>
                    <measurement group_id="O4" value="-1.99" lower_limit="-3.38" upper_limit="-0.63"/>
                    <measurement group_id="O5" value="-1.24" lower_limit="-2.70" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.506</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.02</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.96</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.838</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>1.61</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.82</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Seated, Triplicate Trough Heart Rate</title>
        <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough heart rate.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Seated, Triplicate Trough Heart Rate</title>
          <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures.</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for seated, triplicate, trough heart rate.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.07" spread="9.713"/>
                    <measurement group_id="O2" value="78.73" spread="8.446"/>
                    <measurement group_id="O3" value="77.30" spread="11.749"/>
                    <measurement group_id="O4" value="75.63" spread="9.550"/>
                    <measurement group_id="O5" value="77.97" spread="11.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4</title>
        <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough heart rate.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated, Triplicate Trough Heart Rate at Week 4</title>
          <description>Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for sitting, triplicate trough heart rate.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" lower_limit="0.85" upper_limit="3.82"/>
                    <measurement group_id="O2" value="-1.86" lower_limit="-3.35" upper_limit="-0.38"/>
                    <measurement group_id="O3" value="1.22" lower_limit="-0.28" upper_limit="2.71"/>
                    <measurement group_id="O4" value="-1.51" lower_limit="-3.01" upper_limit="-0.01"/>
                    <measurement group_id="O5" value="-0.99" lower_limit="-2.44" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.20</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.30</ci_lower_limit>
            <ci_upper_limit>-2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.248</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.84</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.95</ci_lower_limit>
            <ci_upper_limit>-1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With terms for treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.33</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.40</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline 24-hour Average Urinary Glucose Excretion</title>
        <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours).</description>
        <time_frame>24 hours</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average urinary glucose excretion</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline 24-hour Average Urinary Glucose Excretion</title>
          <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours).</description>
          <population>All randomized participants who received at least one dose of study drug and had a baseline measurement for average urinary glucose excretion</population>
          <units>grams/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.35" spread="22.913"/>
                    <measurement group_id="O2" value="9.97" spread="20.085"/>
                    <measurement group_id="O3" value="8.04" spread="13.135"/>
                    <measurement group_id="O4" value="17.56" spread="29.101"/>
                    <measurement group_id="O5" value="6.96" spread="8.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4</title>
        <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours). In the case of missing data, LOCF.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for 24-hour urinary glucose excretion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline on 24-hour Urinary Glucose Excretion at Week 4</title>
          <description>Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as &gt;20 hours and &lt;28 hours). In the case of missing data, LOCF.</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement for 24-hour urinary glucose excretion.</population>
          <units>grams/day</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="-3.50" upper_limit="11.81"/>
                    <measurement group_id="O2" value="46.33" lower_limit="38.79" upper_limit="53.88"/>
                    <measurement group_id="O3" value="64.54" lower_limit="56.77" upper_limit="72.31"/>
                    <measurement group_id="O4" value="74.49" lower_limit="66.87" upper_limit="82.11"/>
                    <measurement group_id="O5" value="-0.48" lower_limit="-7.76" upper_limit="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>42.18</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.42</ci_lower_limit>
            <ci_upper_limit>52.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>60.39</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.47</ci_lower_limit>
            <ci_upper_limit>71.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>70.34</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.58</ci_lower_limit>
            <ci_upper_limit>81.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.713</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with treatment as fixed effect and baseline as a covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-4.63</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.22</ci_lower_limit>
            <ci_upper_limit>5.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Fasting Plasma Glucose (FPG)</title>
        <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Fasting Plasma Glucose (FPG)</title>
          <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
          <population>All randomized participants.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.47" spread="51.073"/>
                    <measurement group_id="O2" value="158.38" spread="40.806"/>
                    <measurement group_id="O3" value="158.29" spread="42.465"/>
                    <measurement group_id="O4" value="172.03" spread="55.878"/>
                    <measurement group_id="O5" value="156.87" spread="36.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 4</title>
        <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement at Week 4 for FPG (observed cases).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 4</title>
          <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement at Week 4 for FPG (observed cases).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" lower_limit="-2.16" upper_limit="10.94"/>
                    <measurement group_id="O2" value="-13.70" lower_limit="-20.35" upper_limit="-7.06"/>
                    <measurement group_id="O3" value="-30.41" lower_limit="-37.12" upper_limit="-23.71"/>
                    <measurement group_id="O4" value="-31.03" lower_limit="-37.74" upper_limit="-24.32"/>
                    <measurement group_id="O5" value="3.79" lower_limit="-2.74" upper_limit="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-18.10</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.45</ci_lower_limit>
            <ci_upper_limit>-8.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-34.81</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.19</ci_lower_limit>
            <ci_upper_limit>-25.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-35.42</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.78</ci_lower_limit>
            <ci_upper_limit>-26.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.61</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.86</ci_lower_limit>
            <ci_upper_limit>8.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG at Week 2</title>
        <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement at Week 2 for FPG (observed cases).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG at Week 2</title>
          <description>For FPG, blood was drawn after an overnight fast of at least 8 hours (except water).</description>
          <population>Analysis population consisted of all randomized participants who received at least 1 dose of blinded treatment and had baseline measurement and post-randomization measurement at Week 2 for FPG (observed cases).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.44" lower_limit="-11.93" upper_limit="1.04"/>
                    <measurement group_id="O2" value="-10.98" lower_limit="-17.69" upper_limit="-4.26"/>
                    <measurement group_id="O3" value="-22.45" lower_limit="-29.23" upper_limit="-15.67"/>
                    <measurement group_id="O4" value="-32.03" lower_limit="-38.66" upper_limit="-25.40"/>
                    <measurement group_id="O5" value="3.21" lower_limit="-3.32" upper_limit="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.224</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-5.54</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.89</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-17.00</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.39</ci_lower_limit>
            <ci_upper_limit>-7.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value rounded to thousandths.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-26.59</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.84</ci_lower_limit>
            <ci_upper_limit>-17.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.886</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>Mixed Model for Repeated Measures</method>
            <method_desc>With treatment, visit, and treatment-by-visit interaction as fixed effects, participant as random effect and baseline FPG as the covariate.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>8.65</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>17.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
        <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.</description>
        <time_frame>Up to 63 days (including run-in, treatment period, and follow-up)</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Adverse Event (AE)</title>
          <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug.</description>
          <population>Analysis population consisted of all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.</description>
        <time_frame>Up to 28 days (treatment period)</time_frame>
        <population>Analysis population consisted of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
          </group>
          <group group_id="O5">
            <title>HCTZ 12.5mg</title>
            <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE.</description>
          <population>Analysis population consisted of all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 63 days (including screening and run-in [pre-randomization], treatment period, and follow-up)</time_frame>
      <desc>Serious adverse events include all randomized participants who received at least one dose of study drug except for the pre-randomization arm that includes all randomized participants. Non-serious adverse events include all randomized participants who received at least one dose of study drug (all arms).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for Ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to HCTZ, once daily for 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo to ertugliflozin (25 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="E4">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo to ertugliflozin (1 mg or 5 mg), and placebo to HCTZ, once daily for 28 days</description>
        </group>
        <group group_id="E5">
          <title>HCTZ 12.5mg</title>
          <description>HCTZ 12.5 mg, placebo to ertugliflozin (1 mg or 5 mg and 25 mg), once daily for 28 days</description>
        </group>
        <group group_id="E6">
          <title>Pre-randomization</title>
          <description>Blinded placebo was administered for at least 21 days prior to randomization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Athralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

